Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7692582 | 1.00 | CCR2 (0.47) | CCR2PDE5ALMNAPPARAPPARD | |
| SCHEMBL7571098 | 1.00 | CCR2 (0.47) | CCR2PDE5ALMNAPPARAPPARD | |
| SCHEMBL7565423 | 0.95 | CCR2 (0.44) | CCR2PDE5ALMNAPPARAPPARD | |
| SCHEMBL7565896 | 0.95 | CCR2 (0.44) | CCR2PDE5ALMNAPPARAPPARD | |
| SCHEMBL7565420 | 0.95 | CCR2 (0.44) | CCR2PDE5ALMNAPPARAPPARD | |
| SCHEMBL7368352 | 0.86 | PDE5A (0.50) | PDE5APPARAPPARDPPARG | |
| SCHEMBL7368350 | 0.86 | PDE5A (0.50) | PDE5APPARAPPARDPPARG | |
| SCHEMBL7369160 | 0.84 | PPARA (0.47) | PDE5ALMNAPPARAPPARDPPARG | |
| SCHEMBL7364158 | 0.84 | PPARA (0.47) | CCR2PDE5APPARAPPARDPPARG | |
| SCHEMBL7364151 | 0.84 | PPARA (0.47) | CCR2PDE5APPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | CCR2 4407/4885PDE5A 3/4885LMNA 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.